BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 15667537)

  • 1. Anti-tumour response despite loss of donor chimaerism in patients treated with non-myeloablative conditioning and allogeneic stem cell transplantation.
    Dey BR; McAfee S; Colby C; Cieply K; Caron M; Saidman S; Preffer F; Shaffer J; Tarbell N; Sackstein R; Sachs D; Sykes M; Spitzer TR
    Br J Haematol; 2005 Feb; 128(3):351-9. PubMed ID: 15667537
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Allogeneic hematopoietic cell transplantation without myeloablative conditioning for patients with advanced hematologic malignancies.
    Gürman G; Arat M; Ilhan O; Konuk N; Beksaç M; Celebi H; Ozcan M; Arslan O; Ustün C; Akan H; Uysal A; Koç H
    Cytotherapy; 2001; 3(4):253-60. PubMed ID: 12171713
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intentional induction of mixed chimerism and achievement of antitumor responses after nonmyeloablative conditioning therapy and HLA-matched donor bone marrow transplantation for refractory hematologic malignancies.
    Spitzer TR; McAfee S; Sackstein R; Colby C; Toh HC; Multani P; Saidman S; Weyouth DW; Preffer F; Poliquin C; Foley A; Cox B; Andrews D; Sachs DH; Sykes M
    Biol Blood Marrow Transplant; 2000; 6(3A):309-20. PubMed ID: 10905768
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of prophylactic donor leukocyte infusions on mixed chimerism, graft-versus-host disease, and antitumor response in patients with advanced hematologic malignancies treated with nonmyeloablative conditioning and allogeneic bone marrow transplantation.
    Dey BR; McAfee S; Colby C; Sackstein R; Saidman S; Tarbell N; Sachs DH; Sykes M; Spitzer TR
    Biol Blood Marrow Transplant; 2003 May; 9(5):320-9. PubMed ID: 12766882
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Successful allogeneic stem cell transplantation with nonmyeloablative conditioning in patients with relapsed hematologic malignancy following autologous stem cell transplantation.
    Dey BR; McAfee S; Sackstein R; Colby C; Saidman S; Weymouth D; Poliquin C; Vanderklish J; Sachs DH; Sykes M; Spitzer TR
    Biol Blood Marrow Transplant; 2001; 7(11):604-12. PubMed ID: 11760148
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Response and toxicity of donor lymphocyte infusions following T-cell depleted non-myeloablative allogeneic hematopoietic SCT from 3-6/6 HLA matched donors.
    Rizzieri DA; Dev P; Long GD; Gasparetto C; Sullivan KM; Horwitz M; Chute J; Chao NJ
    Bone Marrow Transplant; 2009 Feb; 43(4):327-33. PubMed ID: 18850014
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mixed chimaerism is common at the time of acute graft-versus-host disease and disease response in patients receiving non-myeloablative conditioning and allogeneic stem cell transplantation.
    Mattsson J; Uzunel M; Brune M; Hentschke P; Barkholt L; Stierner U; Aschan J; Ringdén O
    Br J Haematol; 2001 Dec; 115(4):935-44. PubMed ID: 11843830
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prophylactic donor lymphocyte infusions after moderately ablative chemotherapy and stem cell transplantation for hematological malignancies: high remission rate among poor prognosis patients at the expense of graft-versus-host disease.
    de Lima M; Bonamino M; Vasconcelos Z; Colares M; Diamond H; Zalcberg I; Tavares R; Lerner D; Byington R; Bouzas L; da Matta J; Andrade C; Carvalho L; Pires V; Barone B; Maciel C; Tabak D
    Bone Marrow Transplant; 2001 Jan; 27(1):73-8. PubMed ID: 11244440
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reduced-intensity transplantation with in vivo T-cell depletion and adjuvant dose-escalating donor lymphocyte infusions for chemotherapy-sensitive myeloma: limited efficacy of graft-versus-tumor activity.
    Peggs KS; Mackinnon S; Williams CD; D'Sa S; Thuraisundaram D; Kyriakou C; Morris EC; Hale G; Waldmann H; Linch DC; Goldstone AH; Yong K
    Biol Blood Marrow Transplant; 2003 Apr; 9(4):257-65. PubMed ID: 12720218
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-T-lymphocyte globulin based non-myeloablative stem cell transplantation followed by HLA-identical donor lymphocyte infusion for hematologic malignancies.
    Mao P; Wang S; Wang H; Li Q; Xu Y; Mo W; Ying Y; Zhu Z
    Chin Med J (Engl); 2003 Jan; 116(1):70-3. PubMed ID: 12667392
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of nonmyeloablative allogeneic stem-cell transplantation after failure of autologous transplantation in patients with lymphoproliferative malignancies.
    Branson K; Chopra R; Kottaridis PD; McQuaker G; Parker A; Schey S; Chakraverty RK; Craddock C; Milligan DW; Pettengell R; Marsh JC; Linch DC; Goldstone AH; Williams CD; Mackinnon S
    J Clin Oncol; 2002 Oct; 20(19):4022-31. PubMed ID: 12351600
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Matched and mismatched allogeneic stem-cell transplantation from unrelated donors using combined graft-versus-host disease prophylaxis including rabbit anti-T lymphocyte globulin.
    Finke J; Schmoor C; Lang H; Potthoff K; Bertz H
    J Clin Oncol; 2003 Feb; 21(3):506-13. PubMed ID: 12560442
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Allogeneic stem cell transplantation following non-myeloablative conditioning: favorable results in 21 high risk patients with hematological malignancies treated in the Utrecht University Medical Center, the Netherlands].
    Petersen EJ; Lokhorst HL; Verdonck LF
    Ned Tijdschr Geneeskd; 2003 Nov; 147(47):2328-32. PubMed ID: 14669540
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A pilot study of prophylactic donor lymphocyte infusions to prevent relapse in adult acute lymphoblastic leukemias after allogeneic hematopoietic stem cell transplantation.
    Lutz C; Massenkeil G; Nagy M; Neuburger S; Tamm I; Rosen O; Dörken B; Arnold R
    Bone Marrow Transplant; 2008 May; 41(9):805-12. PubMed ID: 18195682
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeted pretransplant host lymphocyte depletion prior to T-cell depleted reduced-intensity allogeneic stem cell transplantation.
    Bishop MR; Steinberg SM; Gress RE; Hardy NM; Marchigiani D; Kasten-Sportes C; Dean R; Pavletic SZ; Gea-Banacloche J; Castro K; Hakim F; Krumlauf M; Read EJ; Carter C; Leitman SF; Fowler DH
    Br J Haematol; 2004 Sep; 126(6):837-43. PubMed ID: 15352988
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Outcome and long-term follow-up of alloreactive donor lymphocyte infusions given for relapse after myeloablative allogeneic hematopoietic stem cell transplantations (HSCT).
    Michallet AS; Nicolini F; Fürst S; Le QH; Dubois V; Hayette S; Bourgeot JP; Tremisi JP; Thomas X; Gebuhrer L; Michallet M
    Bone Marrow Transplant; 2005 Mar; 35(6):601-8. PubMed ID: 15756285
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early host CD8 T-cell recovery and sensitized anti-donor interleukin-2-producing and cytotoxic T-cell responses associated with marrow graft rejection following nonmyeloablative allogeneic bone marrow transplantation.
    Kraus AB; Shaffer J; Toh HC; Preffer F; Dombkowski D; Saidman S; Colby C; George R; McAfee S; Sackstein R; Dey B; Spitzer TR; Sykes M
    Exp Hematol; 2003 Jul; 31(7):609-21. PubMed ID: 12842706
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Unmanipulated HLA 2-3 antigen-mismatched (haploidentical) stem cell transplantation using nonmyeloablative conditioning.
    Ogawa H; Ikegame K; Yoshihara S; Kawakami M; Fujioka T; Masuda T; Taniguchi Y; Hasei H; Kaida K; Inoue T; Kim EH; Kawase I
    Biol Blood Marrow Transplant; 2006 Oct; 12(10):1073-84. PubMed ID: 17084371
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I study of high-stringency CD8 depletion of donor leukocyte infusions after allogeneic hematopoietic stem cell transplantation.
    Orti G; Lowdell M; Fielding A; Samuel E; Pang K; Kottaridis P; Morris E; Thomson K; Peggs K; Mackinnon S; Chakraverty R
    Transplantation; 2009 Dec; 88(11):1312-8. PubMed ID: 19996931
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.